Wockhardt is currently trading at Rs. 679.05, down by 10.50 points or 1.52% from its previous closing of Rs. 689.55 on the BSE.
The scrip opened at Rs. 667.00 and has touched a high and low of Rs. 685.00 and Rs. 659.00 respectively. So far 1,64,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1748.20 on 02-Dec-2015 and a 52 week low of Rs. 659.00 on 23-Nov-2016.
Last one week high and low of the scrip stood at Rs. 744.00 and Rs. 659.00 respectively. The current market cap of the company is Rs. 7,465.00 crore.
The promoters holding in the company stood at 74.26%, while Institutions and Non-Institutions held 8.73% and 16.98% respectively.
Wockhardt’s step down subsidiary - CP Pharmaceuticals, Wrexham, United Kingdom, has been issued a Warning Letter by the US Food and Drug Administration (USFDA). Currently, there is no business being conducted from CP Pharmaceuticals to the US Market.
The company has already initiated required steps to address the concerns raised by USFDA and will be responding to the Agency within the prescribed time.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
